Piramal Pharma Limited has shared its financial results for the first quarter ended June 30^th, 2024.

Revenue from Operations grew by 12% YoY in Q1FY25, driven by robust high-teen growth in the CDMO business and steady double-digit growth in the India Consumer Healthcare Business (ICH) business. The Complex Hospital Generic (CHG) business grew 2% YoY.

Nandini Piramal, Chairperson, Piramal Pharma Limited said, “We have had a good start to the financial year with a steady all-round performance. We delivered a healthy revenue growth accompanied by over 170bps YoY expansion in EBIDTA margin driven by favorable revenue mix and cost optimization initiatives.”

The CDMO business continues to witness sustained order inflows, especially for on-patent commercial manufacturing. The company says it is also seeing good demand for its differentiated offerings with an increase in customer enqiiries and visits. In its CHG business, its planned expansion for its inhalation anesthesia portfolio is on track and is expected to get commercialized in FY26. The India Consumer Healthcare business is also delivering steady growth driven by power brands and strong traction in e-commerce channel.

“As a responsible organization, we are taking good strides in our journey towards building sustainable operations, Piramal added. “Our continuous efforts in quality and compliance bore fruits with successful closure of USFDA inspections at two of our facilities at Lexington (USA) and PPDS (Analytical Services, India).

The company expects its H2 to outperform its H1, both in terms of revenue and profitability.